Badawy Sherif, Vickery Rodney, Shah Keyur, Hussain Munir
Pharmaceutical Research Institute, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, USA.
Pharm Dev Technol. 2004 Aug;9(3):239-45. doi: 10.1081/pdt-200031417.
The effect of some processing and formulation variables on the stability of tablets containing a crystalline salt of a triazine derivative was studied. The salt has a relatively low melting point and a low microenvironmental pH due to the weakly basic nature of the parent compound (pKa = 4.0). This compound decomposes through acid-catalyzed hydrolysis. A full factorial design was used to study the effect of three variables on tablet stability: aqueous wet granulation, ball milling of the salt and filler prior to manufacturing, and the inclusion of sodium carbonate in the formulation as a pH modifier. In addition to the factorial design experiments, a batch of tablets was prepared by wet granulation, using sodium bicarbonate as the pH modifier. Stability of the drug in tablets was evaluated at 40 degrees C/75% relative humidity (RH) and at 40 degrees C/ambient humidity. Stability of tablets was adversely affected by wet granulation. However, stability was greatly improved by wet granulation in the presence of sodium carbonate. While sodium carbonate enhanced drug stability in the tablets, regardless of the manufacturing process, wet granulated tablets were more stable than tablets containing sodium carbonate and prepared without wet granulation. Similarly prepared tablets by using sodium bicarbonate were remarkably less stable compared with those containing sodium carbonate. The use of sodium bicarbonate as a pH modifier resulted in only marginal enhancement of tablet stability, suggesting that a higher microenvironmental pH than that provided by sodium bicarbonate is needed to maximize stability. Despite the low lattice energy of the salt and the potential for disruption of salt crystallinity by mechanical stress, milling did not appear to have an adverse effect on tablet stability under the current experimental conditions. This study shows that selection of the proper manufacturing process, in conjunction with the appropriate pH modifier, could be critical to dosage form stability.
研究了一些加工和制剂变量对含有三嗪衍生物结晶盐片剂稳定性的影响。由于母体化合物的弱碱性(pKa = 4.0),该盐具有相对较低的熔点和较低的微环境pH值。该化合物通过酸催化水解分解。采用全因子设计研究了三个变量对片剂稳定性的影响:水相湿法制粒、制粒前盐和填充剂的球磨以及制剂中加入碳酸钠作为pH调节剂。除了因子设计实验外,还采用湿法制粒制备了一批片剂,使用碳酸氢钠作为pH调节剂。在40℃/75%相对湿度(RH)和40℃/环境湿度下评估了药物在片剂中的稳定性。湿法制粒对片剂稳定性有不利影响。然而,在碳酸钠存在下进行湿法制粒可大大提高稳定性。尽管无论制造工艺如何,碳酸钠均可提高片剂中药物的稳定性,但湿法制粒片剂比不含碳酸钠且未进行湿法制粒制备的片剂更稳定。与含有碳酸钠的片剂相比,使用碳酸氢钠制备的类似片剂稳定性明显较差。使用碳酸氢钠作为pH调节剂仅使片剂稳定性略有提高,这表明需要比碳酸氢钠提供的更高微环境pH值才能使稳定性最大化。尽管该盐的晶格能较低,且机械应力可能破坏盐的结晶度,但在当前实验条件下,球磨似乎对片剂稳定性没有不利影响。这项研究表明,选择合适的制造工艺并结合适当的pH调节剂对剂型稳定性至关重要。